WPG Radiance Pharmaceuticals is a Bit Worse Off! Musk's Private Research Team: The NH Plan?

What finally calmed Ronald down was the nature of Radiance Pharmaceuticals. It was a publicly listed company, and Ronald was merely its CEO—the highest decision-maker in management, not its owner.

Above Ronald was the board of directors. Ronald himself held very little equity in Radiance Pharmaceuticals, so he chose to let things take their course.

Besides, what would reporting this to the board even accomplish?

Radiance Pharmaceuticals' top ten shareholders were all capital behemoths. The largest shareholder was Vanguard Group, the second was BlackRock Capital, and the third was State Street Capital.

Weren't all of those White Eagles capital giants?

If it were crudely simplified, it was like the meat had been stewed tender and was still sitting in the pot.

With that in mind, Ronald silently considered the price of the "generic" HFAA.

Only after careful consideration did Ronald reply, "Our generic HFAA costs 400 dollars per unit to produce. We are willing to sell it to you at cost."

This so-called cost price was actually Nova Pharmaceuticals' most favorable price.

The most favorable price Nova Pharmaceuticals had agreed upon with Five Watches was 2,500 Xia Guo Yuan per Rescue Heart Pill, which came to nearly 400 dollars. So they rounded it off to 400 dollars.

Faced with Ronald's offer, the representatives of the three factions all expressed their satisfaction. They had investigated the price of the Rescue Heart Pill and knew very well just how low 400 dollars was.

Based on HFAA's current price, each of them asking for two thousand HFAA was equivalent to making around thirty million dollars, wasn't it?

Naturally, they were very satisfied!

Since they had reached an agreement on the price, the negotiations naturally became amicable, and the "generic" HFAA was quickly handed over.

After the representatives of the three major factions left,